Asylum seekers and healthcare

UK - Over 100,000 asylum seekers have been relocated throughout London and England's southeast, to spread the cost of their medical care.

However, because many of these people are from countries where HIV and AIDS are rife, many doctors have pointed out that their dispersal may lead to increased HIV transmission in the UK. Additionally, the relocations might not only harm those who might contract the disease, but the asylum seekers themselves, i.e. those already undergoing medical investigations, or beginning antiretroviral therapy, or alternative therapy after drug regimes had failed, or whose care involves multiple medical specialities. Dispersal should also not be considered for those with full-blown AIDS.

A survey of 56 employees in sexual health clinics in London revealed concern that dispersal of asylum seekers was often done within just 48 hours of their arrival, and often without the transfer of their medical details. Only three centres reported appropriate transfer of care.

The doctors argued that before the decision to disperse, the National Asylum Support Service (NASS) should consider expert medical advice, as well as consider the impact on the infrastructure and staffing of sexual health clinics taking over these cases.

However, the Home Office said that the NASS did consider medical conditions and dispersed asylum seekers with hi considerations into there was no evidence that dispersal increased the likelihood of onward transmission of HIV to others, and it was working with HIV or AIDS to areas with suitable medical services.


Read all latest stories

Related articles


Article • Treating Ebola

An isolation unit flying on 60-metre wings

The ‘Robert Koch’ plane for medical evacuations (MedEvac) is the winged equivalent of a German hospital isolation ward. Within it, medics with viral haemorrhagic fever while working on the Ebola…


Article •

The ‘sepsis team’

‘We are all aware of the importance of early diagnosis and rapid appropriate treatment of patients with severe sepsis. Yet, many patients still do not receive satisfactory early management and the…


News • "Gene scissors" vs. sickle cell disease

FDA approves first CRISPR/Cas therapy

It's an important milestone for gene editing technology: a novel treatment for sickle cell disease utilizing CRISPR-Cas9, has now received FDA approval – a first for this type of therapy.

Related products

Subscribe to Newsletter